Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

A community meeting organized by Easton council members to allow residents to hear more about a massive warehouse project ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a hit in recent years and the company has been looking to bridge the revenue ...

Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors ...

Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...